Plasma adropin level in patients with pseudoexfoliation

Area of Science:

• Ophthalmology
• Endocrinology
• Biochemistry

Background:

• Pseudoexfoliation (PEX) syndrome is an age-related condition characterized by the production of abnormal fibrillar extracellular material.
• Adropin is a peptide hormone involved in lipid and glucose metabolism, with potential roles in various physiological processes.

Purpose of the Study:

• To investigate and compare plasma adropin levels in patients diagnosed with pseudoexfoliation (PEX) syndrome and PEX-associated glaucoma versus healthy controls.
• To explore potential correlations between adropin levels and metabolic parameters in PEX patients.

Main Methods:

• A retrospective case-control study was conducted involving 35 patients with PEX and 35 age- and sex-matched healthy controls.
• Plasma adropin concentrations were measured and compared between groups.
• Levels of triglycerides, total cholesterol, LDL, HDL, and HbA1c were also assessed.

Main Results:

• Patients with PEX exhibited significantly lower mean plasma adropin levels compared to the control group (P < 0.001).
• No significant differences in adropin levels were observed between PEX syndrome and PEX glaucoma subgroups.
• No significant differences were found in metabolic parameters (triglycerides, cholesterol, LDL, HDL, HbA1c) or BMI between PEX patients and controls.

Conclusions:

• Plasma adropin levels are demonstrably lower in individuals with pseudoexfoliation (PEX).
• The findings suggest a potential role for adropin in the pathophysiology of PEX, independent of common metabolic risk factors.
• Further research is recommended to elucidate the specific mechanisms linking adropin deficiency to PEX.